Get notified when ACTU files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsActuate Therapeutics receives FDA clearance to begin Phase 1/2 trial of elraglusib
Filed May 11, 2026 · Period ending May 11, 2026 · ~1 min read
Key Changes
-
high
FDA cleared the company's Investigational New Drug application for elraglusib, enabling Actuate to begin Phase 1/2 clinical testing in human subjects—a critical regulatory milestone in drug development.
Item 8.01 view on EDGAR → -
medium
Company announced plans to advance the elraglusib development program following the IND clearance, though specific timelines and trial design details were not disclosed in the 8-K.
Press Release verify on EDGAR →
This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (FNGR 10-Q) is open in full — no account needed.
Partner
Trade ACTU commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 1, 2026 · How we verify